Malta - angličtina - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - fluvastatin - hard capsule - fluvastatin 40 mg - lipid modifying agents

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - fluvastatin sodium, quantity: 84.24 mg (equivalent: fluvastatin, qty 80 mg) - tablet, modified release - excipient ingredients: hypromellose; hyprolose; potassium bicarbonate; magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide; macrogol 8000; iron oxide yellow - hypercholesterolaemia: prior to initiating therapy with fluvastatin for treating hypercholesterolaemia, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. adults: as an adjunct to diet in the treatment of hypercholesterolaemia. heterozygous familial hypercholesterolaemia in paediatric patients: as an adjunct to diet in adolescent boys and in adolescent girls who are at least one year post-menstruation, 10-16 years of age, with heterozygous familial hypercholesterolaemia whose response to dietary restriction has not been adequate and in whom the following findings are present: 1. ldl-c remains greater than or equal to 4.9 mmol/l (190 mg/dl) or 2. ldl-c remains greater than or equal to 4.1 mmol/l (160 mg/dl) and: there is a positive family history of premature cardiovascular disease - or two or more other cardiovascular disease risk factors are present. secondary prevention of cardiac events: for the prevention of major adverse cardiac events in adult patients with coronary heart disease who have undergone successful coronary transcatheter therapy.

Spojené štáty - angličtina - NLM (National Library of Medicine)

carilion materials management - fluvastatin sodium (unii: pyf7o1fv7f) (fluvastatin - unii:4l066368as) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. fluvastatin capsules are indicated: the ncep classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cvd is summarized below. category total-c (mg/dl) ldl-c (mg/dl) acceptable < 170 < 110 borderline 170 to 199 110 to 129 high ≥ 200 ≥ 130 children treated with fluvastatin in adolescence should be reevaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. in patients with clinically evident chd, fluvastatin capsules are indicated to: fluvastatin capsules have not been studied in conditions wh

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - fluvastatin sodium - capsule - 40 milligram

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - fluvastatin sodium - capsule - 20 milligram

Spojené štáty - angličtina - NLM (National Library of Medicine)

physicians total care, inc. - fluvastatin sodium (unii: pyf7o1fv7f) (fluvastatin - unii:4l066368as) - fluvastatin sodium 80 mg - therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see national cholesterol education program [ncep] treatment guidelines, below). lescol® (fluvastatin sodium) and lescol® xl (fluvastatin sodium) are indicated to reduce elevated total cholesterol (total-c), ldl-c, tg and apo b levels, and to increase hdl-c in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. lescol and lescol xl are indicated as an adjunct to diet to reduce total-c, ldl-c, and apo b levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: - ldl-c remains > 190 mg/dl or - ldl-c remains > 160 mg/dl and:

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - fluvastatin sodium - oral capsule - 20mg

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - fluvastatin sodium - oral capsule - 20mg

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - fluvastatin sodium - oral capsule - 20mg

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - fluvastatin sodium - oral capsule - 20mg